Show simple item record

dc.contributor.authorMachhi, Jatin
dc.contributor.authorShahjin, Farah
dc.contributor.authorDas, Srijanee
dc.contributor.authorPatel, Milankumar
dc.contributor.authorAbdelmoaty, Mai Mohamed
dc.contributor.authorCohen, Jacob D
dc.contributor.authorSingh, Preet Amol
dc.contributor.authorBaldi, Ashish
dc.contributor.authorBajwa, Neha
dc.contributor.authorKumar, Raj
dc.contributor.authorVora, Lalit K
dc.contributor.authorPatel, Tapan A
dc.contributor.authorOleynikov, Maxim D
dc.contributor.authorSoni, Dhruvkumar
dc.contributor.authorYeapuri, Pravin
dc.contributor.authorMukadam, Insiya
dc.contributor.authorChakraborty, Rajashree
dc.contributor.authorSaksena, Caroline G
dc.contributor.authorHerskovitz, Jonathan
dc.contributor.authorHasan, Mahmudul
dc.contributor.authorOupicky, David
dc.contributor.authorDas, Suvarthi
dc.contributor.authorDonnelly, Ryan F
dc.contributor.authorHettie, Kenneth S
dc.contributor.authorChang, Linda
dc.contributor.authorGendelman, Howard E
dc.contributor.authorKevadiya, Bhavesh D
dc.date.accessioned2021-02-22T17:45:28Z
dc.date.available2021-02-22T17:45:28Z
dc.date.issued2021-02-05
dc.identifier.urihttp://hdl.handle.net/10713/14743
dc.description.abstractExtracellular vesicles (EVs) are the common designation for ectosomes, microparticles and microvesicles serving dominant roles in intercellular communication. Both viable and dying cells release EVs to the extracellular environment for transfer of cell, immune and infectious materials. Defined morphologically as lipid bi-layered structures EVs show molecular, biochemical, distribution, and entry mechanisms similar to viruses within cells and tissues. In recent years their functional capacities have been harnessed to deliver biomolecules and drugs and immunological agents to specific cells and organs of interest or disease. Interest in EVs as putative vaccines or drug delivery vehicles are substantial. The vesicles have properties of receptors nanoassembly on their surface. EVs can interact with specific immunocytes that include antigen presenting cells (dendritic cells and other mononuclear phagocytes) to elicit immune responses or affect tissue and cellular homeostasis or disease. Due to potential advantages like biocompatibility, biodegradation and efficient immune activation, EVs have gained attraction for the development of treatment or a vaccine system against the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection. In this review efforts to use EVs to contain SARS CoV-2 and affect the current viral pandemic are discussed. An emphasis is made on mesenchymal stem cell derived EVs’ as a vaccine candidate delivery system. Graphical Abstract: [Figure not available: see fulltext.]. © 2021, The Author(s)en_US
dc.description.urihttps://doi.org/10.1007/s11481-020-09981-0en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofJournal of NeuroImmune Pharmacologyen_US
dc.subjectCoronavirus disease 2019 (COVID-19)en_US
dc.subjectExtracellular vesicles (EVs)en_US
dc.subjectMesenchymal stem cells (MSCs)en_US
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)en_US
dc.titleA Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Preventionen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s11481-020-09981-0
dc.identifier.pmid33544324
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record